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ORIGINAL ARTICLE
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Background: Walker-Warburg syndrome (WWS) is an autosomal recessive condition characterised by
congenital muscular dystrophy, structural brain defects, and eye malformations. Typical brain
abnormalities are hydrocephalus, lissencephaly, agenesis of the corpus callosum, fusion of the
hemispheres, cerebellar hypoplasia, and neuronal overmigration, which causes a cobblestone cortex.
Ocular abnormalities include cataract, microphthalmia, buphthalmos, and Peters anomaly. WWS patients
show defective O-glycosylation of a-dystroglycan (a-DG), which plays a key role in bridging the
cytoskeleton of muscle and CNS cells with extracellular matrix proteins, important for muscle integrity and
neuronal migration. In 20% of the WWS patients, hypoglycosylation results from mutations in either the
protein O-mannosyltransferase 1 (POMT1), fukutin, or fukutin related protein (FKRP) genes. The other
genes for this highly heterogeneous disorder remain to be identified.
Objective: To look for mutations in POMT2 as a cause of WWS, as both POMT1 and POMT2 are required
to achieve protein O-mannosyltransferase activity.
Methods: A candidate gene approach combined with homozygosity mapping.
Results: Homozygosity was found for the POMT2 locus at 14q24.3 in four of 11 consanguineous WWS
families. Homozygous POMT2 mutations were present in two of these families as well as in one patient
from another cohort of six WWS families. Immunohistochemistry in muscle showed severely reduced levels
of glycosylated a-DG, which is consistent with the postulated role for POMT2 in the O-mannosylation
pathway.
Conclusions: A fourth causative gene for WWS was uncovered. These genes account for approximately
one third of the WWS cases. Several more genes are anticipated, which are likely to play a role in
glycosylation of a-DG.
W
alker-Warburg syndrome (WWS) is a congenital
disorder characterised by multiple anomalies of the
brain, muscle, and eye. This combination of
malformations is also found in muscle-eye-brain disease
(MEB) and in Fukuyama congenital muscular dystrophy
(FCMD). The most severe anomalies are seen in WWS
patients, especially with regard to the brain malformations.
Brain malformations typical of WWS are agyria, agenesis of
the corpus callosum, cerebellar vermis and septum, and
occasional occipital encephalocele.1–3 The pathogenesis
underlying WWS, MEB, FCMD, and other congenital
muscular dystrophies (CMD) such as congenital muscular
dystrophy 1C (MDC1C) and 1D (MDC1D) involves functional
disruption of a-dystroglycan (a-DG) by mutations in genes
that are involved in O-mannosylation of this protein.4–10 The
O-linked carbohydrate chains of a-DG are an important
component of the dystrophin glycoprotein complex which
mediates the interaction between the extracellular matrix
and the cytoskeleton of muscle cells and neurones.11–15 A
common O-mannosyl glycan structure found on a-DG is
NeuAca2-3Galb1-4GlcNAcb1-2Man-Ser/Thr.16 17 The first
step in the synthesis of this glycan structure takes place in
the endoplasmic reticulum by one or more proteins from a
family of well conserved protein O-mannosyltransferases
(PMTs). These proteins catalyse the transfer of a mannose
from dolichyl phosphate activated mannose to serine or
threonine residues of secretory proteins. In yeast, a family
of seven PMTs (Pmt1p to Pmt7p) are known. Double and
triple mutants of the PMTs in yeast indicate that proper
O-mannosylation is required for its cell wall rigidity and cell
integrity.18 In Drosophila and human there are only two
orthologues: POMT1 and POMT2.16 RNAi knockdown of
either POMT1 or POMT2 in Drosophila causes a rotation of the
abdomen by 30–60 ,̊ demonstrating the requirement of both
POMT1 and POMT2 for normal muscle development in the
fly.19 No embryonic nervous system or eye abnormalities were
observed for POMT1 knockouts.20 In addition, it has been
shown that in humans POMT1 and POMT2 are also both
required for O-mannosyltransferase activity.19 21 Previously
we have shown that mutations in either POMT1, FCMD, or
FKRP result in hypoglycosylation of a-DG, giving rise to the
autosomal recessive disorder WWS.22–24 The phenotypic
similarity seen in the fly knockdown of POMT1 and POMT2
and the simultaneous requirement for both proteins to obtain
O-mannosyltransferase in fly as well as human made us
reconsider POMT2 as candidate gene for WWS. In this study
we show that POMT2 mutations also cause WWS.
METHODS
Genetic analysis
Using standard methods we extracted DNA from peripheral
blood lymphocytes. Genome-wide homozygosity mapping
was carried out at our linkage facility using the 10 cM spaced
Abbreviations: a-DG, a-dystroglycan; CMD, congenital muscular
dystrophy; FCMD, Fukuyama congenital muscular dystrophy; MEB,




microsatellite marker set from Applied Biosystems (ABI
Prism linkage mapping set version 2, Applied Biosystems,
Foster City, California, USA) and at MRC geneservice in
Cambridge with use of the GeneChip Mapping 10K 2.0 array
from Affymetrix (Santa Clara, California, USA). Additional
homozygosity mapping for POMT2 was undertaken by
polymerase chain reaction (PCR) of the flanking microsa-
tellite markers D14S279, D14S983, and D14S59, which were
subsequently resolved on 8% polyacrylamide sequencing gels
and developed by silver staining.
Mutation analysis
All 21 exons of the POMT2 gene were amplified using specific
primers for the 59- and 39-flanking intron sequences. Primers
and PCR conditions are given in table 1. After purification
from agarose gels, the PCR products were used for direct
sequencing using the BigDye terminator kit (Perkin Elmer
Applied Biosystems, Norwalk, Connecticut, USA), which
were analysed on an ABI3700 capillary sequencer. The
presence of the identified mutations in the normal popula-
tion was tested by restriction enzyme analysis in chromo-
somes from control individuals. For this, the relevant
amplicon was digested with TaqI (c.1912CRT), HpyCH4 IV
(c.1005+1GRA), and NciI (c.1261delC) (New England
BioLabs, Beverly, Massachusetts, USA).
Immunohistochemistry
Muscle biopsies from control and WWS patients were
obtained after informed consent of patients and approval of
the ethics commission. Myoblast cell cultures were estab-
lished by enzymatic and mechanical treatment of muscle
biopsies and by plating in Dulbecco’s modified Eagle’s
Table 1 Primer sequences and conditions for PCR reaction





1 ggagttgcagttccctgagc taccctcgggccaatcagag 609 58
2 ccatgctttatgaaggccatttg tggctccagcccttaggaac 224 58
3 gcagctggagggaagttcag ttagtgtggccccagggttc 235 58
4 tcatcaggtcccctgtcttaaatg gggcccttgaatgtactgattttc 294 58
5 gtttcctactactggggtgcttgg acagaaattttggagttgccacag 250 58
6 aagacagggcacagcacagc ccagaacacagccactctgc 384 58
7 ggctggcccatgtttatcttg agggtgctggcctttctgag 502 58
8 tccatcacccacctctgtcc ctttctcccaccgtgccatc 339 58
9 ttagtgagccctgtggcttcc tgtcatggcgaacagcattg 255 58
10 tggctggggattctgaaattg tcagcaaagcccatctcagg 304 58
11 ggggtctttcctctttggtctc tgtggccttgctccattgac 353 58
12 ggtttgggctcatctcttctcc tccctgtgcagcctcttatcc 403 58
13 gccatttccctttctgacacg gcagacagcaggtgaacacag 334 58
14 ggaaaagagaaggagcctgtgg cggagggagtggatgagaag 386 58
15 ctggtgggaatgtggacacc attcatggctgcccaaaagc 214 58
16 ctgggccccacatttctgtc cggtctccctgctcttgttc 203 58
17 tcctccccctaatgggtgtg ggaatgggcagatgagaacg 207 58
18 gcgttctcatctgcccattc ggtggtaaacgcaaaggatgg 246 58
19 acagcaaggaaggggcagag tgctctgtctcccaagtccag 263 58
20 cctggctgactccaggtttc acactgggagggcatgtgag 185 58
21 agctccagcaggaggaatgg ttccagctgcactcccagag 342 58
Figure 1 POMT2 mutations in families
with Walker-Warburg syndrome
(WWS). For each of the families with
POMT2 mutations the pedigrees and
DNA sequencing results are shown.
Mutations are indicated with an asterisk
(*). Patient 1 is homozygous for a
nonsense mutation in exon 19
(c.1912CRT, p.R638X). The mutation
in this patient is preceded by a known
polymorphism indicated by a dagger
() sign. Patient 2 is homozygous for a
mutation in intron 8 (c.1005+1GRA)
which is predicted32 to result in the
disruption of the donor site for intron
splicing of intron 8. This mutation also
disrupts a restriction site for the
HpyCH4 IV enzyme and was not
present in 100 chromosomes of
controls. Patient 3 is homozygous for a
deletion of 1 bp in exon 12
(c.1261delC) which tends to a
premature stop codon (p.T433X). The
same mutation was found
heterozygously in both parents and
homozygously in an affected sibling in
this family.
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medium plus fetal calf serum (FCS), penicillin, streptomycin,
and amphotericin B (Sigma, Poole, Dorset, UK).25 Myotubes
were obtained by confluent myoblast cultures allowed to
differentiate for seven days in cultures medium. Samples for
immunohistochemical analysis were fixed in 2% paraformal-
dehyde in phosphate buffer saline (PBS) and incubated
overnight with an anti-a-dystroglycan monoclonal antibody
(VIA4-1, Upstate Biotechnology, Lake Placid, New York,
USA) diluted 1/50, washed with PBS and then with an anti-
mouse IgG TRITC conjugated antibody (Dako, Glostrup,
Denmark). The same sample was then incubated with a
polyclonal anti-caveolin 3 antibody (Santa Cruz
Biotechnology, Santa Cruz, California, USA) diluted 1/50
followed by FITC conjugated anti-goat antibody. The sample
was washed in PBS, mounted in Pro-long anti-fade reagent
(Molecular Probes, Eugene, Oregon, USA), and examined
with a Nikon epifluorescence microscope at a magnification
of6100.
Immunohistochemistry on muscle biopsies was carried out
as described by Jimenez-Mallebrera et al.26 In Brief, frozen
8 mm sections were incubated with primary monoclonal
antibodies to b-DG (NCL-b-DG, Novocastra Laboratories,
Newcastle upon Tyne, UK), a-DG (IIH6, Upstate
Biotechnology), and sheep polyclonal antibody recognising
the core protein of a-DG.27 These were than revealed with an
appropriate biotinylated secondary antibody (Amersham
1:200; Amersham Life Sciences, Amersham, UK) followed
incubation with streptavidin conjugated to Alexa 594
(Molecular Probes) and visualised by epifluorescence micro-
scopy.
RESULTS
Direct linkage mapping of candidate genes using
genome-wide homozygosity data
We carried out genome-wide homozygosity mapping of 12
WWS patients from 11 unrelated consanguineous families in
which linkage to the known WWS loci (POMT1, Fukutin, and
FKRP) has been excluded. Depending on the amount of DNA
available we used the 10 cM spaced microsatellite marker set
(ABI Prism linkage mapping set version 2) or the GeneChip
Mapping 10K 2.0 Array (Affymetrix). As can be expected
from the genetic heterogeneity of WWS, these homozygosity
mapping results of mostly singletons failed to point to a
single WWS locus and indeed indicated further genetic
heterogeneity. Although we failed to detect POMT2 mutations
in an earlier study of 24 WWS families,22 we targeted POMT2
as a candidate gene based on the premise that all three
previously identified WWS genes—POMT1, fukutin and
FKRP—are involved in O-mannosyl glycan synthesis. A
similar function is likely for POMT2, based on the over-
lapping expression profiles and homologous amino acid
composition compared with POMT1. In addition, recent
reports indicate that POMT2 is required for the enzymatic
activity of POMT1 in human as well as Drosophila.19 21 Our
new mapping data indicated possible linkage to the POMT2
locus in four of 11 unrelated WWS families.
Mutation analysis of POMT2
Mutation analysis in all four families led to the identification
of mutations in two of these, a nonsense mutation
(c.1912CRT, p.R638X) in patient 1 and a splice site mutation
Figure 2 Brain magnetic resonance
imaging of patient 1 at two days of age
(A and B) and patient 2 at 16 months of
age (C and D). Both patients show
hydrocephalus, dilatation of the
ventricles, agyria, cerebellar
hypoplasia, and absence of the corpus
callosum.
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(c.1005+1GRA) in patient 2, both found in homozygosity.
Both mutations result in the disruption of a restriction site
for Taq1 and HpyCH4 IV, in exon 19 and exon 8, respectively.
These disruptions were not observed in control individuals
digested with Taq1 (170 chromosomes) and HpyCH4 IV (290
chromosomes). No mutations were detected in the POMT2
exons in the other two families that showed linkage to the
POMT2 locus. Reasons for this could be that their linkage was
a fortuitous finding or that a mutation resides in parts of the
POMT2 gene such as an intron or regulatory elements that
have not been analysed. An additional six consanguineous
WWS families were then tested for homozygosity at the
POMT2 locus. In two of these WWS families the data were
consistent with linkage to POMT2. We identified a homo-
zygous 1 base pair (bp) deletion (c.1261delC) in one these
families. This mutation introduces a premature stop codon
(p.T433X). The mutation was also homozygously present in
an affected sibling and disrupts one of the two restriction
sites for NciI in exon 12, which was used the verify the
absence of this mutation in 140 control chromosomes from
the normal population. Pedigrees and DNA sequencing
results of the three POMT2 mutated families are shown in
fig 1.
Clinical description WWS patients with POMT2
mutations
Patient 1 is a girl born to uncle-niece consanguineous
Moroccan parents. A prenatal ultrasound indicated hydro-
cephalus which was confirmed by magnetic resonance
imaging, which also showed type II lissencephaly (fig 2,
panels A and B). At birth at 37 weeks gestation, weight was
3150 grams, and head circumference 36 cm. The child was
severely hypotonic. Ophthalmological examination showed
bilateral Peters anomaly with cataracts, left sided micro-
phthalmia, and right sided buphthalmos. The creatine kinase
was greatly raised at 12 144 U/l. MRI of the brain
documented hydrocephalus, cobblestone lissencephaly, and
aplasia of the corpus callosum.
Patient 2 is a male child born to first cousin Pakistani
parents. Severe hydrocephalus was diagnosed prenatally on
ultrasound and the child was delivered by caesarean section.
A left sided cleft lip and palate was diagnosed. Imaging of the
brain by MRI revealed aplasia of the posterior vermis,
hypoplasia of the pons and cerebellum, and severe hydro-
cephalus and cobblestone cortex (fig 2, panels C and D).
Ophthalmological investigation documented bilateral catar-
acts and persistent pupillary membrane. The retina could not
be visualised. A muscle biopsy was consistent with a
diagnosis of congenital muscular dystrophy. There was
increased variability of fibre diameter, increased endomysial
fibrosis, and basophilic regeneration. External genitalia were
normal. The child died at the age of six months.
Patient 3 is a male infant referred at the age of two months
and one week because of severe neonatal hypotonia,
developmental delay, and poor visual behaviour, as pre-
viously reported.26 He was the third child of a consanguineous
Bengali family. His older siblings were healthy. Congenital
hydrocephalus required a shunt at two weeks of age. Serum
creatine kinase was markedly raised. Ophthalmological
examination showed bilateral lamellar cataracts, and
buphthalmos caused by anterior chamber anomalies. He
had no head control and no apparent response to visuoa-
coustical stimuli. Brain MRI at the age of five weeks showed
severe hydrocephalus with a thin and smooth cortical mantle.
The patient died at eight months of age during a respiratory
infection.
A further sibling was diagnosed prenatally with severe
hydrocephalus at 18 weeks’ gestation. This pregnancy was
subsequently terminated.
Histopathology of WWS muscle tissue
Immunolabelling of the glycoepitope of a-DG with the VIA4-
1 antibody28 in cultured myotubes from patient 2 showed
severely reduced staining compared with control myotubes
(fig 3, panels A and B). Control labelling with anti-caveolin3,
a marker of muscle differentiation, showed that a-DG
Figure 3 Immunofluorescence analysis
of cultured myotubes obtained from a
control individual (A and C) and
patient 2 (B and D). A double labelling
was carried out with anti-a-DG glyco-
epitope antibody (VIA4-1) (A and B),
and anti-caveolin3, a marker of muscle
differentiation (C and D). These were
visualised using an anti-mouse TRITC
conjugated secondary antibody and an
anti-goat FITC conjugated antibody,
respectively. In control myotube, a-DG
labelling co-localises with caveolin3 at
the sarcolemma. In the WWS patient
myotube, caveolin 3 was expressed
with a pattern similar to the control
myotube while a-DG staining was
severely reduced. Magnification6500.
a-DG, a-dystroglycan; WWS, Walker-
Warburg syndrome.
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co-localises with caveolin3 at the sarcolemma of myotubes
derived from a control individual (fig 3C). Similar normal
staining was observed in myotubes derived from patient 2
(fig 3D). Reduced staining of a-DG was also observed in
patient 3 by immunolabelling of the core and glyco-epitope of
a-DG (fig 4, panels D and F). Normal staining was observed
for a-DG in control muscle (fig 4, panels C and E). b-DG
staining was normal in the patient as well as in the control
(fig 4, panels A and B). Reduction of immunolabelling of a-
DG and a mild reduction of laminin-a2 in muscle tissue from
patient 3 were described previously by Jiminez-Mallebrera et
al.26 No muscle tissue was available for patient 1.
DISCUSSION
We have detected three homozygous mutations in POMT2 in
three families with typical WWS. The mutations included a
nonsense mutation resulting in a premature stop codon, a
splice site mutation, and a 1 bp deletion leading to a
premature stop codon. All mutations were homozygous in
the patients (fig 1). The phenotype seen in these WWS
patients is indistinguishable from that of patients with
POMT1, FCMD, or FKRP mutations. One of the sibpair from
family 3 who carries a homozygous 1 bp deletion mutation
was described earlier, and hypoglycosylation of a-DG (fig 4)
and a possible reduction of laminin-a2 in muscle tissue was
documented.26 Absence of glycosylated a-DG was also seen in
a muscle biopsy from patient 2 in the present study (fig 3).
This is consistent with the postulated role of O-glycosylation
in normal neuromuscular, brain, and eye development.11 29
Although previously no enzymatic activity of POMT1 and
POMT2 was determined in vertebrates, the involvement of
POMT1 in WWS, the high amino acid identity between the
two paralogues, and the overlapping expression pattern was
reason to hypothesise that mutations in POMT2 also give rise
to WWS.30 For this reason we previously undertook mutation
analysis of POMT2 in 24 unrelated patients but no causative
mutations were detected.22 In this study, 17 additional
families where investigated, of which six showed possible
linkage to the POMT2 locus. We found POMT2 mutations in
three of these (fig 1), resulting in a frequency of 7% (3 of 41
families). Thus the incidence of POMT2 mutations appears to
be in the same range as that of POMT1. POMT1 mutations
were previously detected at a frequency of 20% and 7% in two
large samples of WWS patients.22 31 This is in accordance with
the requirement of both proteins to obtain O-mannosyl-
transfererase activity.19 21 So far, mutations in POMT1, POMT2,
fukutin, and FKRP together explain almost one third of the
WWS patients in our cohort. The majority of WWS cases
remain unexplained and further genetic heterogeneity is
likely from our genome-wide homozygosity data.
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